Phase
Condition
Warts
Rosacea
Skin Wounds
Treatment
Placebo
piclidenoson
Clinical Study ID
Ages > 18 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
Male or female, 18 years and above;
Diagnosis of moderate-to-severe chronic plaque-type psoriasis with BSA involvement ≥10%;
PASI score ≥12 at the Screening and Baseline visits;
Static PGA ≥3 at the Screening and Baseline visits;
Candidate for systemic treatment or phototherapy for psoriasis;
Duration of psoriasis of at least 12 months;
Females of childbearing potential must have a negative serum pregnancy test atscreening;
Female subjects of childbearing potential must use at least one acceptablecontraceptive method throughout the course of the trial and for 1 month after thelast dose of study medication;
Male subjects must refrain from sperm donation during treatment and until at least 1month after the last dose of study medication. Male subjects must agree to usecondoms throughout the course of the trial and for 1 month after the last dose ofstudy medication;
Ability to complete the study in compliance with the protocol; and
Ability to understand and provide written informed consent.
Exclusion
Exclusion Criteria:
Psoriasis limited to erythrodermic, guttate, palmar, plantar, or generalizedpustular psoriasis in the absence of plaque psoriasis;
Treatment with systemic retinoids, systemic corticosteroids, tofacitinib,apremilast, immunosuppressive agents (e.g., methotrexate, cyclosporine), or anyother approved drugs for the indication of plaque psoriasis (e.g., deucravacitinib)within 4 weeks of the Baseline visit;
Treatment with a monoclonal antibody or other biologic agent for psoriasis within 8weeks for etanercept, adalimumab, or infliximab, or within 12 weeks for all otheragents, prior to the Baseline visit;
Treatment with Vitamin D analogs, keratolytics, coal tar (other than on the scalp,palms, groin, and/or soles), any topical corticosteroid, calcineurin inhibitors,vitamin A analogs, retinoids, anthralin, calcipotriene, tazarotene, methoxsalen,trimethyl-psoralens, fumarate, PDE4 inhibitors, or aryl hydrocarbonreceptor-modulating agents within 2 weeks of the Baseline visit;
Ultraviolet or Dead Sea therapy within 4 weeks of the Baseline visit, or anticipatedneed for either of these therapies during the study period;
Treatment with lithium, hydroxychloroquine or chloroquine within 2 weeks of theBaseline visit, or anticipated need for such drugs during the study period, unlessdose has been stable for 3 months prior to the Screening visit and will remainstable throughout the trial;
Estimated glomerular filtration rate (eGFR) ≥50 mL/min/1.73m2 by the Modification ofDiet in Renal Disease equation at Screening (NOTE: In Segment 2, a renally-impairedsubgroup of at least 10 12 subjects with eGFR of 20-49 mL/min/1.73m2 will beenrolled for PK analysis purposes);
Liver aminotransferase levels greater than 1.5 times the laboratory's upper limit ofnormal at Screening;
QTcF interval > 450 milliseconds (msec) for males or > 470 msec for females onScreening Visit and Baseline visit ECGs (average of triplicate ECGs at each visit) (except when QT prolongation is associated with right or left bundle branch block orcardiac pacemaker, in which case enrollment is allowed);
A condition which increases proarrhythmic risk, including hypokalemia,hypomagnesemia, or congenital Long QT Syndrome;
Ongoing or planned use of a concomitant medication that is on the CredibleMedsTMlist of drugs known to cause Torsades des Pointes;
Active gastrointestinal disease which could interfere with the absorption of oralmedication;
Pregnancy, planned pregnancy, lactation, or inadequate contraception as judged bythe Investigator;
Active drug or alcohol dependence;
Concomitant use of strong cytochrome P450 inducers, e.g., rifampin, phenobarbital,phenytoin, carbamazepine;
PHQ-9 score ˃ 4 at baseline;
Any significant/uncontrolled neuropsychiatric illness judged as clinicallysignificant by the investigator during screening or at Day 1, or any lifetimehistory of suicidal ideation, suicidal behavior, or suicidal attempts by medicalhistory or by Columbia Suicide Severity Rating Scale (C-SSRS) documentation, or byanswering "yes" to Question 4 or 5 for suicidal ideation on the C-SSRS at screeningor at Day 1, or is clinically deemed to have a suicide risk by the investigator;
Previous participation in a piclidenoson (CF101) clinical trial;
Significant acute or chronic medical or psychiatric illness that, in the judgment ofthe Investigator, could compromise subject safety, limit the subject's ability tocomplete the study, and/or compromise the objectives of the study; and
Participation in another investigational drug or vaccine trial concurrently orwithin 30 days prior to the Screening visit.